Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
Bi
CAS Number:
Molecular Weight:
208.98
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141706
MDL number:
Product Name
Bismuth, foil, 25x25mm, thickness 0.25mm, 100%
InChI
1S/Bi
SMILES string
[Bi]
InChI key
JCXGWMGPZLAOME-UHFFFAOYSA-N
vapor pressure
<0.1 mmHg ( 20 °C)
assay
100%
form
foil
manufacturer/tradename
Goodfellow 899-185-00
resistivity
129 μΩ-cm, 20°C
bp
1560 °C (lit.)
mp
271 °C (lit.)
density
9.8 g/mL at 25 °C (lit.)
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ruiguang Ge et al.
Metallomics : integrated biometal science, 4(3), 239-243 (2012-02-24)
Helicobacter pylori causes various gastric diseases, such as gastritis, peptic ulcerations and gastric cancer. Bismuth-based triple or quadruple therapies have been commonly recommended for the treatment of H. pylori infections. Up to now, the molecular mechanisms by which bismuth inhibits
Syntheses of biodegradable and biocompatible polymers by means of bismuth catalysts.
Hans R Kricheldorf
Chemical reviews, 109(11), 5579-5594 (2009-09-26)
Jorge A R Salvador et al.
Future medicinal chemistry, 4(11), 1495-1523 (2012-08-04)
In recent years, the chemical potential of bismuth and bismuth compounds has been actively exploited. Bismuth salts are known for their low toxicity, making them potential valuable reagents for large-scale synthesis, which becomes more obvious when dealing with products such
Bismuth in medicine.
Hongzhe Sun et al.
Metal ions in biological systems, 41, 333-378 (2004-06-23)
P Moayyedi et al.
Alimentary pharmacology & therapeutics, 17(10), 1215-1227 (2003-05-21)
Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting. To conduct a systematic review evaluating these therapies in non-ulcer dyspepsia. Electronic searches were performed using the Cochrane Controlled Trials
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service